Kelly Lorenz, MD
Ophthalmology · Anchorage, AKNPI 1508068636
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 71 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. AbbVie accounts for 66.7% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $1,049, 9.8 times the $107 reported in 2019.
Across 71 payments — averaging $29.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Alcon$244
- NEW World Medical,inc.$62
- Bausch & Lomb, A Division Of Bausch Health US, LLC$59
- Oyster Point Pharma, Inc.$49
- Mallinckrodt Hospital Products Inc.$49
- plus $223 from 10 others
What the payments were for
- Food & beverage$2,064100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 44 | $1,378 |
| Alcon | 6 | $244 |
| NEW World Medical,inc. | 3 | $62 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 3 | $59 |
| Oyster Point Pharma, Inc. | 2 | $49 |
| Mallinckrodt Hospital Products Inc. | 2 | $49 |
| Genentech USA, Inc. | 1 | $34 |
| Bausch & Lomb Americas Inc. | 2 | $34 |
| Katena Products, Inc. (dba Corza Medical) | 1 | $33 |
| Alimera Sciences, Inc. | 1 | $24 |
| Biotissue Holdings Inc. | 1 | $19 |
| Shire North American Group Inc | 1 | $19 |
| Novartis | 1 | $17 |
| Sight Sciences, Inc. | 1 | $15 |
| Tarsus Pharmaceuticals, Inc. | 1 | $15 |
| Glaukos Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- XEN GLAUCOMA TREATMENT SYSTEM$342
- LUMIGAN$118
- DURYSTA$118
How this compares
$2,064 in reported general payments places this provider in the 65th percentile of 30 ophthalmology providers in Alaska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 153 | $95,225 |
| RestasisCyclosporine | 19 | $31,398 |
| CombiganBrimonidine Tartrate/Timolol | 51 | $27,962 |
| Brimonidine Tartrate | 250 | $22,388 |
| RocklatanNetarsudil Mesylat/Latanoprost | 25 | $18,582 |
| Cyclosporine | 28 | $18,482 |
| RhopressaNetarsudil Mesylate | 17 | $16,874 |
| VyzultaLatanoprostene Bunod | 22 | $15,400 |
| Travoprost | 46 | $9,833 |
| Alphagan PBrimonidine Tartrate | 15 | $9,597 |
| ZioptanTafluprost/Pf | 11 | $9,113 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 33 | $8,194 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 25 | $8,139 |
| Timolol MaleateTimolol Maleate/Pf | 16 | $7,233 |
| TafluprostTafluprost/Pf | 19 | $7,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Combigan, Alphagan P | $1,378 | $164,182238 claims |
| Bausch & Lomb Americas Inc.Vyzulta | $34 | $15,40022 claims |
| AlconSimbrinza | $244 | $8,13925 claims |
| NovartisTravatan Z | $17 | $5,15911 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 30 ophthalmology providers in Alaska.
Other ophthalmology in Anchorage
- Eric CoulterAnchorage$7K
- Carl RosenAnchorage$4K
- Elizabeth MorganAnchorage$3K
- Don DavisAnchorage$3K
- Eileen MyersAnchorage$2K
- Scott LimstromAnchorage$2K
- Griffith SteinerAnchorage$747
- David ZumbroAnchorage$429
- David ChamberlainAnchorage$408
- James FordAnchorage$373
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.